Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03347318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease

Study acronym: PROFILING
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Mar 31, 2026 to Mar 15, 2026
    • Site details revised at 15 of 15 sites
    v3
  2. Primary completion date: Jun 2018 to Mar 31, 2026
    • Start date: Jan 2011 to Mar 30, 2011
    • Study completion date: Dec 2021 to Mar 31, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to define the molecular profile of selected solid tumors. From each participants will be collected biological materials for molecular analysis, including saliva, blood and vital tumor tissue derived form surgical or biopsy procedures. Whereas possible, vital tumor specimens will be inoculated and propagated in immunocompromised NOD/SCID mice to study the genetic correlations between genetic status and response to target drugs.
Trial Details
NCT Number NCT03347318
Lead Sponsor Fondazione del Piemonte per l'Oncologia
Conditions
(from sponsor)		 Solid Tumors
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov